Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype MTBDRsl version 2 and phenotypic drug resistance detection of <i>Mycobacterium tuberculosis</i> for fluoroquinolones and aminoglycosides.

International journal of mycobacteriology·2023
Same author

CRISPR/Cas genome editing in plants: Dawn of Agrobacterium transformation for recalcitrant and transgene-free plants for future crop breeding.

Plant physiology and biochemistry : PPB·2023
Same author

Hepatoprotective Constituents of Macrocybe gigantea (Agaricomycetes) from India.

International journal of medicinal mushrooms·2022
Same author

In vitro growth inhibitory effect of selected 18β-glycyrrhetinic acid esters on Theileriaannulata.

Experimental parasitology·2022
Same author

Improving abiotic stress tolerance in sorghum: focus on the nutrient transporters and marker-assisted breeding.

Planta·2021
Same author

Bluemomycin, a new naphthoquinone derivative from Streptomyces sp. with antimicrobial and cytotoxic properties.

Biotechnology letters·2021

Related Experiment Video

Updated: Jul 18, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Cinnamaldehyde--a potential antidiabetic agent.

P Subash Babu1, S Prabuseenivasan, S Ignacimuthu

  • 1Division of Ethnopharmacology, Entomology Research Institute, Loyola College, Chennai 600 034, Tamil Nadu, India.

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|December 5, 2006
PubMed
Summary

Cinnamaldehyde, isolated from cinnamon, effectively lowers blood glucose and improves lipid profiles in diabetic rats. This study validates cinnamon

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Related Experiment Videos

Last Updated: Jul 18, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Area of Science:

  • Pharmacology and Toxicology
  • Natural Product Chemistry
  • Endocrinology

Background:

  • Cinnamon (Cinnamomum zeylanicum) is traditionally used for diabetes management in India.
  • Bioassay-guided fractionation is a method to isolate active compounds from medicinal plants.
  • Streptozotocin (STZ) is commonly used to induce diabetes in experimental animal models.

Purpose of the Study:

  • To isolate and identify antidiabetic compounds from cinnamon.
  • To evaluate the hypoglycemic and hypolipidemic effects of the isolated compound, cinnamaldehyde.
  • To determine the safety profile of cinnamaldehyde through LD50 determination.

Main Methods:

  • Bioassay-guided fractionation to isolate the active compound.
  • Chemical and physicochemical methods for structure determination of cinnamaldehyde.
  • Administration of cinnamaldehyde to streptozotocin-induced diabetic rats and assessment of various biochemical parameters.
  • Comparison with glibenclamide as a reference drug.

Main Results:

  • Cinnamaldehyde was identified as the active antidiabetic compound.
  • Significant dose-dependent reduction in plasma glucose levels (up to 63.29%) was observed.
  • Improved glycemic control (decreased HbA1c, increased insulin and hepatic glycogen) and lipid profiles (decreased cholesterol and triglycerides, increased HDL-C).
  • Restoration of altered plasma enzyme levels towards normal.

Conclusions:

  • Cinnamaldehyde exhibits significant hypoglycemic and hypolipidemic effects in STZ-induced diabetic rats.
  • The findings support the traditional use of cinnamon for diabetes treatment.
  • Cinnamaldehyde is a potential therapeutic agent for managing diabetes.